Alembic Prescription drugs posted its outcomes for the quarter ended December 2024 (Q3FY25). Its consolidated internet revenue tumbled 23.29 % to ₹138.42 crore in Q3 FY25, in contrast with ₹180.45 crore posted in Q3 FY24. Nonetheless, income from operations was at ₹1,692.74 crore within the third quarter of FY25, up 3.81 % yr on yr (YoY).
EBITDA elevated by 1 % YoY to ₹271 crore, with an EBITDA margin of 16 % in Q3 FY25.
Administration Commentary
Shaunak Amin, MD, Alembic Prescription drugs Restricted stated. “Within the present quarter, we confronted market headwinds within the acute phase. Nonetheless, different key therapies in our specialty enterprise continued to outpace the market progress. To strengthen subject pressure effectivity, now we have enhanced Automation and AI, to upscale execution. This Transition has partly impacted quarter progress. We’re assured to point out a strong progress trajectory going ahead. The US Enterprise posted vital quantity progress and the Ex-US markets continued to develop steadily. API Enterprise continues to be beneath vital pricing strain.”
Publish the earnings, the inventory fell over 5 % to its day’s low of ₹888.35.
